Search the Newsreel

Concrete Pumping (NASDAQ:BBCP) Rating Lowered to "Hold" at Zacks Research

Zacks Research has downgraded Concrete Pumping (NASDAQ:BBCP) from "strong buy" to "hold" following the company's recent earnings report where it missed EPS estimates but exceeded revenue expectations. Despite the downgrade, the broader analyst consensus remains a "Moderate Buy" with a $10.25 target price. Insiders …

CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Inc. reported its second-quarter 2026 financial results, highlighting significant progress in clinical, regulatory, manufacturing, and commercial-readiness initiatives. Key milestones include anticipated Phase 3 topline data for PIVOT-006, expected BLA completion for HR BCG-unresponsive NMIBC in Q4 2026, and the publication of BOND-003 …

CG Oncology expects bladder cancer trial data soon; cash through 2029

CG Oncology reported a Q2 2026 net loss of $79.1 million on $1.2 million in revenue, primarily due to increased R&D and G&A expenses. The company maintains a strong cash position of approximately $1.0 billion, which is projected to fund operations through 2029, supporting …

Cullinan to begin potentially registrational acute myeloid leukemia study in Q3

Cullinan Therapeutics reported a Q2 2026 net loss of $53.7 million but maintained a strong cash position of $356 million, providing a runway into 2029. The company announced several upcoming clinical milestones for its immunology and oncology pipeline, including the initiation of a potentially …

Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Pyxis Oncology Inc (PYXS), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that 10 analysts have given the stock a "Buy" trend, with an average price target of $7.70. The article …

Ponce Financial Group, Inc. Q2 2026: Net income $8.21M, EPS $0.35— 10-Q Summary

Ponce Financial Group, Inc. reported strong Q2 2026 results with net income increasing to $8.21M, a 41.2% year-over-year change, and diluted EPS rising to $0.35. This growth was primarily driven by a significant increase in net interest income and margin expansion, alongside strategic shifts …

UBS Group raises BeiGene (ONC.US) target price to $467, citing another earnings beat in the second quarter and naming it a top pick.

UBS Group has raised its target price for BeiGene (ONC.US) to $467, following the company's strong second-quarter earnings performance. The firm reiterated its "Buy" rating and named BeiGene as a top pick, citing its robust product pipeline and favorable market position. This upward revision …

Earnings To Watch: Treace Medical Concepts Inc (TMCI) Q2 2026 -- GF Value Sees 49% Upside

Once Upon a Farm Q2 2026 Earnings: 42% Sales Growth Comes With Margin Pressure

ALX Oncology (NASDAQ:ALXO) Issues Earnings Results

Dickson Concepts Wins Strong Shareholder Backing at 2026 AGM

CG Oncology (CGON) Earnings Date and Reports 2026

Once Upon A Farm (OFRM) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Once Upon a Farm Raises 2026 Sales Outlook to $327M-$335M

Oncology Institute (NASDAQ:TOI) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

[10-Q] Concentra Group Holdings Parent, Inc. Quarterly Earnings Report

Concentra Group Holdings Parent Inc (CON) is scheduled to release its Q2

Beigene Ltd (ONC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Concentrix Solutions Corporation

Concentrix Corporation and its client Currys have won the NiCE 2026 International CX Excellence Award for Excellence in Engagement Orchestration (EMEA). The award recognizes their success in transforming customer engagement through tech-powered operations, intelligent orchestration, and innovation, leading to double-digit satisfaction gains and stronger …

Pacer Advisors Inc. Has $9.72 Million Stock Position in Concentrix Corporation $CNXC

Pacer Advisors Inc. significantly increased its stake in Concentrix Corporation (NASDAQ:CNXC) by 2,107.6% in the first quarter, now holding 355,400 shares valued at $9.72 million. Despite this, analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $32.75 against …

Cullinan Oncology earnings up next: Can pipeline justify cash burn?

Cullinan Therapeutics Inc. is set to report second-quarter earnings, with analysts expecting a wider loss per share. The pre-revenue biotech, with a $1.08 billion market cap, is advancing two late-stage oncology programs, CLN-049 and zipalertinib, which have garnered bullish Wall Street sentiment and significant …

Dimensional Fund Advisors LP Sells 22,459 Shares of CG Oncology, Inc. $CGON

Dimensional Fund Advisors LP has reduced its stake in CG Oncology (NASDAQ:CGON) by selling 22,459 shares, though it still holds 438,673 shares valued at approximately $29.7 million. Despite this sale, institutional investors collectively own 26.56% of the company, and analysts maintain a "Moderate Buy" …

Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025

Levi & Korsinsky LLP has filed a class action securities lawsuit against Treace Medical Concepts, Inc. (NASDAQ:TMCI). The lawsuit alleges that the company made false statements and concealed information regarding competition and demand for its Lapiplasty product, leading to revenue decline. Investors who suffered …

CGON (CGON) insider Ambaw Bellete plans 25,000-share stock sale via broker

CG Oncology, Inc. (CGON) insider Ambaw Bellete has filed a Form 144 notice to sell up to 25,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,837,500.00. The shares, acquired via a stock option exercise, are …

Concentra Group Holdings Parent, Inc. (NYSE: CON) director sells 130,000 shares

Concentra Group Holdings Parent, Inc. (NYSE: CON) director Robert A. Ortenzio sold 130,000 shares of common stock on August 3, 2026, at a weighted average price of $31.8412 per share. The sale, valued at $4.14 million, was executed indirectly through The Rocco A. Ortenzio …

Enterprise value to EBIT forward of Pyxis Oncology, Inc. – NASDAQ:PYXS

This article provides financial information for Pyxis Oncology, Inc. (NASDAQ: PYXS), specifically focusing on its enterprise value to EBIT forward ratio. It highlights that the data is presented by TradingView, a platform offering various market tools and financial insights. The content is primarily a …

BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.71 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 29.6%. EPS of $2.05 for the same period compares to $0.84 a year ago. The reported revenue represents a surprise of …

Citius Oncology's LYMPHIR is in 42 institutions with near-universal coverage

Currys Turns Nearly Six Million Customer Interactions Into Actionable Insights

Concentrix and its client Currys won the NiCE 2026 International CX Excellence Award for Excellence in Engagement Orchestration (EMEA), recognizing their success in transforming customer engagement. The solution, powered by NiCE CXone, unified nearly six million annual interactions into actionable insights, delivering double-digit gains …

BeiGene's H1 Net Profit Surges 627% to 3.27 Billion Yuan; Full-Year Revenue Guidance Raised to 46.2 Billion Yuan

BeiGene reported a significant surge in its H1 2026 net profit, increasing by 627% to 3.27 billion yuan, driven primarily by strong global sales of its core product, Brukinsa. The company has also raised its full-year revenue guidance to a range of 44.9 billion …

Kura Oncology to Report Second Quarter Financial Results

Kura Oncology, Inc. announced it will report its second quarter 2026 financial results after market close on Wednesday, August 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. The company …

Cancer drugmaker Kura Oncology schedules Aug. 12 webcast

Kura Oncology (Nasdaq: KURA) will report its second quarter 2026 financial results after the close of U.S. financial markets on Wednesday, August 12, 2026. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the …

The Oncology Institute, Inc. Revenue Breakdown – NASDAQ:STLN

The Oncology Institute, Inc. (NASDAQ: STLN) generated $502.73 million in revenue last year, with its Dispensary segment being the top performer, contributing $269.18 million. The majority of its revenue, $502.73 million, originated from the United States. This indicates a strong domestic market for the …

Stock Radar: Concord Biotech stock showing signs of rebound after falling over 20% from highs; time to buy

Loan growth lifts Ponce Financial Group (NASDAQ: PDLB) as ECIP targets met

Top Healthcare Stocks to Watch: Why Is OncoSil Medical (ASX:OSL) in Focus?

Behind Concord Healthcare (2453.HK)'s Positive Profit Alert: Gross Profit Surges More Than 160-Fold as Proton Therapy Enters a New Phase of Scalable Growth

Concord Healthcare (2453.HK) has issued a positive profit alert, projecting a significant increase in gross profit for the first half of 2026, surging over 160-fold year-on-year. This remarkable growth is attributed to its proton therapy infrastructure entering a commercialization stage, with the Guangzhou Concord …